Evaluation of COVID-19 Risk in Patients on Systemic Retinoid Therapy

The study evaluated the risk of COVID-19 in 186 patients undergoing systemic retinoid therapy, specifically isotretinoin and acitretin, compared to a control group not on retinoid therapy. Results showed that 1.07% of patients in the retinoid group and 4.3% in the control group were diagnosed with COVID-19, with no cases in patients receiving acitretin. There was no significant difference in COVID-19 incidence or severity between the groups. The study concluded that systemic retinoids did not increase the risk or severity of COVID-19, suggesting they were a safe treatment option during the pandemic.